Skip to main content

Axel S Merseburger

Dr Axel Merseburger is the chairman of the Department of Urology at the University Hospital Schleswig-Holstein in Lübeck, Germany.

His key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors.

He is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer and has served as national and international principal investigator in several phase II/III clinical trials.

His molecular and clinical research has won multiple awards, stipends and prizes, and he has authored and co-authored more that 200 publications.


Latest contributions from Axel Merseburger

Axel Merseburger & Elizabeth Plimack

30-06-2021 | ASCO 2021 | Ask the expert | Video

Key data on urothelial carcinoma presented at ASCO 2021

Elizabeth Plimack and Axel Merseburger highlight interesting trials within the topic of urothelial carcinoma presented at the 2021 ASCO Annual Meeting.

This video is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

Axel Merseburger

02-10-2019 | Genitourinary cancers | Video | Article

Expert highlights: Genitourinary cancers at ESMO 2019

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

Axel Merseburger

01-06-2019 | Castration-sensitive prostate cancer | Video | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

16-03-2018 | Axel S Merseburger | Article

Advisory board comment

Comment on: EBRT plus brachytherapy stands out for high-risk prostate cancer